GCM
RNAC icon

Gladius Capital Management’s Cartesian Therapeutics RNAC Stock Holding History

Gladius Capital Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-571
Closed -$19.2K – 435
2023
Q2 		$19.2K Buy
+571
New +$20.4K ﹤0.01% 307

Other funds holding RNAC

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gladius Capital Management's RNAC Position: Q3 2023 in Review

Gladius Capital Management sold out of Cartesian Therapeutics (RNAC) in Q3 2023, closing a stake of 571 shares — an estimated $19.2K sold.

Gladius Capital Management first reported a position in RNAC in Q2 2023 and held it in 1 quarter. The position peaked at $19.2K in Q2 2023. 87 funds tracked by Wall St. Rank hold RNAC as of Q3 2023.

  • Gladius Capital Management reported no remaining Cartesian Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Gladius Capital Management sold 571 Cartesian Therapeutics shares in Q3 2023, an estimated $19.2K.
  • Gladius Capital Management first reported a position in Cartesian Therapeutics in Q2 2023 and held it in 1 quarter.
  • Gladius Capital Management's Cartesian Therapeutics position peaked at $19.2K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2023.

Based on Gladius Capital Management's 13F filing for Q3 2023, filed 10 Oct 2023.